Table of Content

1. Artificial Immune Modulation Nanotechnology Overview
1.1 Introduction to Artificial Immune Modulation Nanotechnology
1.2 Immunotherapy Inspired Design for Artificial Immune Modulation
1.3 Influence of Antigen Presenting Cells on T-cell Activation


2. Role of Nanotechnology in Enriching Artificial Immune Modulation Platform
2.1 Nanoparticles Contributing to Other Immunotherapies Efficiency
2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation


3. Synthetic Immunology to Engineer Antigen Presenting Cells
3.1 Synthetic Immunology for Already Available Immunotherapy
3.2 Eligibility & Applications of Synthetic Immunology in Artificial Immune Modulation


4. Artificial Immune Modulations for Various Indications
4.1 Immunity - Cancer Cycle Relationship
4.2 Influence of Artificial Immune Modulation Over Cancer
4.3 Influence of Artificial Immune Modulation Against Other Indications


5. T-Cell Enrichment & Expansion (E+E) Technology for Proprietary Artificial Immune Modulation Platform


6. NexImmune Clinical Trials for Artificial Immune Modulation Products
6.1 NEX-001 & NEX-003 for Acute Myeloid Leukemia
6.1.1 Overview
6.1.2 Clinical Insight
6.2 NEX-002 for Multiple Myeloma
6.2.1 Overview
6.2.2 Clinical Insight



7. Recent Trends & Opportunities Available for Expansion of Artificial Immune Modulation Therapy
7.1 Globe Cancer Statistics
7.2 Increasing Popularity of Immunotherapy Treatments
7.3 High Adaptability by Pharmaceutical Companies
7.4 Immunotherapy in Combination with Other Cancer Treatment Methods


8. Estimated Commercial Opportunity for Artificial Immune Modulation Drugs

8.1 Immunotherapies & Price Study for Estimating Artificial Immune Modulation Products Commercial Success
8.1.1 CAR-T Cell Therapy & their Products
8.1.2 Tumor-Infiltrating Lymphocyte Immunotherapy
8.2 AIM Therapy Price Estimates


9. Drivers & Challenges Triggered with the Outcome of Artificial Immune Modulation
9.1 Drivers for Artificial Immune Modulation
9.2 Challenges for Artificial Immune Modulation


10. Future Directions for Artificial Immune Modulation
10.1 Exploring New Avenues for Immunotherapy
10.2 Future Regional Landscape for Artificial Immune Modulation


11. Competitive Landscape



List of Figures


Figure 1-1: Natural Antigen Presentation by Antigen Presenting Cells
Figure 1-2: Artificial Immune Modulation Antigen Presentation
Figure 1-3: Types of Therapies Based on Immunotherapy Principle
Figure 1-4: Results of Antigen Presentation on T-Cells by Antigen Presenting Cells
Figure 1-5: US – Population of Men & Women Living with Auto-Immune Diseases (Million), 2020
Figure 1-6: US – Cancer Statistics (Million), 2019
Figure 2-1: Different Configurations Used in Nano Bio Materials for Medical or Biological Issues
Figure 2-2: Applications of Nanotechnology in Medicines
Figure 2-3: Potential Contribution of Nanoparticles to Immunotherapies
Figure 3-1: Synthetic Immunology Working on Immune Cells
Figure 3-2: Potential Addition of Functions to Engineered Immune Cells
Figure 3-3: Synthetic Immunology & Artificial Immune Modulation Combination
Figure 4 1: Representation of Immune System Attacking Cancer Cells with the help of Antigen Presenting Cells
Figure 4-2: North America – Population above 65 Years of Age (Million), 2018
Figure 4-3: Artificial Immune Modulation Against Cancer
Figure 4-4: US- Auto-Immune Diseases Statistics (Million), 2020
Figure 4-5: Potential Applications for Artificial Immune Modulation in Medical Field
Figure 5-1: Benefits of Clinical Trials in Medical World
Figure 5-2: Enrichment & Expansion Process Overview for Artificial Immune Modulation Platform
Figure 6-1: Ongoing Clinical Trials for Artificial Immune Modulation Platform by NexImmune
Figure 6-2: Robust Pipeline for Artificial Immune Modulation Products
Figure 6-3: US – Estimated Acute Myeloid Leukemia Statistics, 2020
Figure 6-4: US – Acute Myeloid Leukemia New Cancer Cases Statistics (%), 2020
Figure 6-5: US – Acute Myeloid Leukemia Deaths Statistics (%), 2020
Figure 6-6: US – Clinical Trial Status for Artificial Immune Modulation, 2020
Figure 6-7: US – Multiple Myeloma Cancer Statistics, 2020
Figure 6-8: US – Multiple Myeloma Cancer Statistics by Gender, 2020
Figure 6-9: US – Clinical Trial Status for Artificial Immune Modulation
Figure 7-1: Recent Trends & Opportunity for Artificial Immune Modulation Growth
Figure 7-2: Global – Total New Cases of Cancers (Million), 2018
Figure 7-3: Global - Total Cancer Deaths (Million), 2018
Figure 7-4: Global – New Cases of Multiple Myeloma, 2018
Figure 7-5: Global – Total Deaths Due to Multiple Myeloma, 2018
Figure 7-6: Clinical Benefits of using Cancer Immunotherapy
Figure 7-7: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 7-8: US – Active, Not Recruiting Clinical Trials for Immunotherapy vs. Other Cancer Treatment Methods, 2020
Figure 7-9: Pharmaceutical Companies Investing in Immunotherapy Development
Figure 7-10: Global - Roche’s Total Immunological Products Sales (US$ Million), 2015 - 2019
Figure 7-11: Global – Roche Group Sales Increment (%), 2016 - 2019
Figure 7-12: Global – Eli Lilly’s Total Immunological Product Sales (US$ Million), 2017 - 2019
Figure 7-13: Global – Eli Lilly’s Increase in Immunology Revenue due to Taltz (%), 2018 & 2019
Figure 7-14: Potential Combinations for Artificial Immune Modulation
Figure 8-1: Global – CAR-T Cell Therapy Drug Kymriah Treatment Cost vs. Drug Cost (US$ Million), 2020
Figure 8-2: US – Price of CAR-T Cell Therapy Products (US$), 2020
Figure 8-3: Global – Kymriah Total Sales (US$ Million), 2018 & 2019
Figure 8-4: Global – Yescarta Total Sales (US$ Million), 2018 & 2019
Figure 8-5: US – TIL Immunotherapy Minimum & Maximum Treatment Price (US$), 2020
Figure 8-6: Immunotherapy Price Comparison
Figure 8-7: AIM Therapy – Minimum & Maximum Treatment Price Estimates (US$), 2026
Figure 9-1: Cancer Driver for Artificial Immune Modulation Market
Figure 9-2: Potential Drivers for Artificial Immune Modulation
Figure 9-3: Challenges Associated with Artificial Immune Modulation
Figure 10-1: US – Estimated Cancer Care Expenditure by Healthcare (US$ Billion), 2019 & 2026